Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

A strong start to the week
Tue, 27 Jan Closing

The Indian markets surged higher as buying activity increased during the final hour of trade. The BSE-Sensex ended with gains of about 290 points or 1%, while NSE-Nifty closed higher by about 75 points or 0.9%. Barring stocks from the information technology and metals spaces, gains were seen across the board with banking and capital goods stocks leading the pack. Midcaps and smallcaps closed the day on a firm note as well, with their respective indices up by about 0.8% each.

Asian stocks ended firm, while stocks in Europe were trading weak. The rupee was trading at Rs 61.46 to the dollar at the time of writing.

Auto Stocks were in demand today with Tata Motors and Ashok Leyland leading the pack of gainers. Passenger car manufacturer Maruti Suzuki ended the day on a firm note today on the back of company reporting a good set of results for the quarter ended December 2014. The company reported a profit growth of 18% YoY while revenues were up by about 15% YoY. As per the company, it was the higher volumes coupled with cost reduction efforts as well as favourable forex movement which led to a faster rise in profits. Sales volumes for the quarter were higher by 12% YoY at about 323,911 units as compared to 288,151 units in the same period last fiscal. From this, domestic sales formed about 91% of volumes (295,202 units) as against 92% or 268,185 units in the same period last fiscal, while exports formed the balance. Maruti closed higher by about 2.2% today.

Stocks of pharmaceutical companies ended the day on a firm note with Cipla and GSK Pharma leading the pack of gainers. As per as leading business daily, drug major Ranbaxy has stated that the US Food and Drug Administration (FDA) has forfeited the 180 day exclusivity of its tablets which are used to treat stomach and esophagus problems. The company has stated that it would be pursuing all legal routes to preserve its rights. It is believed that the US market size of this drug (Nexium) is approximately US$ 2 bn and since Ranbaxy was holding 6-month exclusivity for this drug, this was an important opportunity for Ranbaxy.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "A strong start to the week". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.